ChinaBio® Today is the most widely-read source for China life science news and analysis. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China life science companies and industry events, as well as global issues affecting the China life science industry.
Week in Review: Kumquat Signs $2 Billion US-China Deal with Lilly for Novel Immune Drugs
July 31, 2021
Deals and Financings San Diego 's Kumquat Biosciences formed a $2 billion partnership with Lilly to discover small molecule tumor-specific immunoncology drugs; Kumquat will retain China rights to the...
Shanghai 's I-Mab has been cleared to start a US Phase I trial of its novel immunotherapy for Alzheimer's. Protollin is composed of outer membrane bacteria proteins complexed with lipopolysaccharides...
Shanghai Zai Lab and Boston 's Entasis Therapeutics have completed enrollment in a global Phase III trial of novel combination antibacterial. Entasis' SUL-DUR combines two IV antibacterial aimed at...
I-Mab Plans Second Listing on Shanghai's STAR Board
July 27, 2021
I-Mab, a Shanghai biotech, announced it is planning to add a listing on the STAR Board of the Shanghai Exchange. The new offering is expected to take place in 2022. In early 2020, I-Mab completed a...
Deals and Financings Qiming, a China-based VC firm, raised more than $500 million for a fund that will invest in shares of listed healthcare companies with a focus on Greater China and Asia;...
Jilin Qilu Pharmaceutical has enrolled the first patient in a China bridging trial of Vicineum in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). One year ago, Qilu...
Junshi Forms $16 Million mRNA JV with Hangzhou's Immorna
July 20, 2021
Eluminex Biosciences ( Suzhou ), an ophthalmology biotech, in-licensed global rights to a biosynthetic cornea developed by FibroGen. The synthetic cornea, which is intended to treat corneal blindness,...
Deals and Financings Beijing InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen in a $937 million deal that including a $125 million upfront payment; Suzhou Innovent Bio announced a...
Grit Biotechnology, a two-year-old Shanghai cell therapy company, closed a Series A+ round to develop its Tumor Infiltrating Lymphocytes (TIL) therapies. Its leading program is GT101, a genetically...